Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma

Nicholas Barasch
Xue Gong
Kevin A. Kwei
Sushama Varma
Jewison Biscocho

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.pacific.edu/dugoni-facarticles

Part of the Dentistry Commons

Recommended Citation
Barasch N, Gong X, Kwei KA, Varma S, Biscocho J, Qu K, et al. (2017) Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma. PLoS ONE 12(2): e0171265. https://doi.org/10.1371/journal.pone.0171265

This Article is brought to you for free and open access by the All Faculty Scholarship at Scholarly Commons. It has been accepted for inclusion in All Dugoni School of Dentistry Faculty Articles by an authorized administrator of Scholarly Commons. For more information, please contact mgibney@pacific.edu.
Authors
Nicholas Barasch, Xue Gong, Kevin A. Kwei, Sushama Varma, Jewison Biscocho, Kunbin Qu, Nan (Tori) Xiao, Joseph S. Lipsick, Robert J. Pelham, Robert B. West, and Jonathan R. Pollack

This article is available at Scholarly Commons: https://scholarlycommons.pacific.edu/dugoni-facarticles/237
Abstract

Pathogenic gene fusions have been identified in several histologic types of salivary gland neoplasia, but not previously in acinic cell carcinoma (AcCC). To discover novel gene fusions, we performed whole-transcriptome sequencing surveys of three AcCC archival cases. In one specimen we identified a novel HTN3-MSANTD3 gene fusion, and in another a novel PRB3-ZNF217 gene fusion. The structure of both fusions was consistent with the promoter of the 5' partner (HTN3 or PRB3), both highly expressed salivary gland genes, driving overexpression of full-length MSANTD3 or ZNF217. By fluorescence in situ hybridization of an expanded AcCC case series, we observed MSANTD3 rearrangements altogether in 3 of 20 evaluable cases (15%), but found no additional ZNF217 rearrangements. MSANTD3 encodes a previously uncharacterized Myb/SANT domain-containing protein. Immunohistochemical staining demonstrated diffuse nuclear MSANTD3 expression in normal salivary ductal epithelium, as well as among other histologic types of salivary gland cancer though without evidence of translocation. In a broader survey, MSANTD3 showed variable expression across a wide range of normal and neoplastic human tissue specimens. In preliminary functional studies, engineered MSANTD3 overexpression in rodent salivary gland epithelial cells did not enhance cell proliferation, but led to significant upregulation of gene sets involved in protein synthesis. Our findings newly identify MSANTD3 rearrangement as a recurrent event in salivary gland AcCC, providing new insight into disease pathogenesis, and identifying a putative novel human oncogene.
Introduction

In cancers, chromosomal translocations and rearrangements can create gene fusions, resulting in the effective overexpression of full-length cancer genes or producing chimeric oncoproteins [1, 2]. Gene fusions were originally considered hallmarks of hematopoietic and mesenchymal cancers, but more recently have been reported in a wide range of epithelial cancer types [2]. Identifying and characterizing gene fusions have provided new molecular insight into disease pathogenesis. Moreover, gene fusions have refined the diagnosis and classification of cancers, and have proven to be effective targets for molecularly-directed therapy. Examples include the classic BCR-ABL fusion in chronic myelogenous leukemia [3], and more recently, EML4-ALK in lung cancer [4].

Salivary gland neoplasms comprise a collection of at least 30 distinct histopathologic subtypes, including malignant epithelial tumors (e.g. acinic cell carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and salivary duct carcinoma) and benign epithelial lesions (e.g. pleomorphic adenoma, basal cell adenoma, oncocytoma, myoepithelioma, and Warthin tumor). Developing mainly in the parotid gland, these diagnoses together account for approximately 6% of all head and neck tumors [5]. Over the past years, recurrent gene fusions have been identified in several different salivary gland neoplasms [6–8], including PLAG1 fusions (most often CTNNB1-PLAG1) and HMGA2 rearrangements in pleomorphic adenoma, CRTC1-MAML2 fusion in mucoepidermoid carcinoma, MYB-NFIB (or MYBL1-NFIB [9, 10]) fusion in adenoid cystic carcinoma, ETV6-NTRK3 fusion in mammary analogue secretory carcinoma of the salivary gland, and EWSR1-ATF1 fusion in hyalinizing clear cell carcinoma. These fusions, impacting cell signaling pathways and cell-cycle regulation, inform neoplastic mechanisms, provide molecular biomarkers for refined diagnosis, and may suggest new opportunities for therapy. Whether other salivary gland neoplasms also harbor recurrent gene fusions has remained an open question.

Acinic cell carcinoma (AcCC) of the salivary gland is a malignant epithelial neoplasm named for its characteristic acinic cell differentiation [11]. AcCC accounts for approximately 5–11% of all salivary gland carcinomas and is considered as a low-grade malignancy, with a five-year disease-specific survival rate of 91% and a lifetime disease-associated death rate of 16% [12, 13]. Little is known about the pathogenesis of AcCC. Furthermore, ancillary tests and the immunoprofile of AcCC are non-specific and thus, diagnosis is made based primarily on morphologic criteria.

Here, to discover pathogenic gene fusions in AcCC, we performed whole transcriptome analysis of three prototypic cases. We report the identification of a novel gene fusion, HTN3-MSANTD3, and recurrent rearrangements of MSANTD3 in 16% of AcCC. A hitherto unstudied gene, we also here surveyed MSANTD3 expression across a diverse set of human tissues and neoplasias, and carried out preliminary studies of its function.

Materials and methods

Tissue specimens

Salivary gland acinic cell carcinoma specimens were identified by an electronic search of the Stanford University Department of Pathology archives. In all, we retrieved formalin-fixed paraffin-embedded (FFPE) blocks for 27 cases dating between 1997 and 2014. Hematoxylin and eosin (H&E) stained tissue sections were reviewed by a pathologist (R.B.W) to confirm the diagnosis. Three AcCC cases were used for the RNA-seq studies, while all 27 were incorporated into a tissue microarray (TMA). All existing archived tissue specimens reported in this publication were used with Stanford University Institutional Review Board approval.
Transcriptome sequencing (RNA-seq)

RNA-seq of FFPE specimens was done as previously reported [14]. Briefly, FFPE blocks were sectioned (10μM thickness), RNA isolated using the Allprep RNA/DNA FFPE kit (Qiagen), and RNA quality verified by Agilent Bioanalyzer. Sequencing libraries (150 bp average insert size) were then prepared from 100 ng of rRNA-depleted RNA using TruSeq RNA Sample Preparation Kit v2 (Illumina), with four indexed libraries loaded per flow-cell lane. Paired-end 75-bp sequencing was carried out on a HiSeq 2000 instrument (Illumina), with the three AcCC libraries yielding 103–110 million sequencing reads. For discovery of gene fusions, evidenced by paired reads mapping to two different genes, and/or reads spanning predicted fusion junctions, we used Chimeriscan [15], TopHat-Fusion [16], SnowShoes-FTD [17], and deFuse [18] software. RNA-seq reads are available at GEO (accession GSE76354). Analysis of publicly-available The Cancer Genome Atlas (TCGA) RNA-seq data was done using Wanderer [19], a web-based interactive viewer.

Tissue microarrays

A TMA comprising 27 AcCC cases was constructed as previously described [20], using a manual tissue arrayer (Beecher Instruments). Each case was represented by two 0.6mm cores. Ten additional TMAs, covering other salivary gland tumor diagnoses as well as normal and neoplastic tissues from diverse anatomic sites, and together representing 1495 cases, were previously described [21, 22].

Fluorescence in situ hybridization

Identified gene rearrangements were validated in TMA tissue sections by “break apart” FISH assay. Custom FISH probes for the MSANTD3 locus were generated from bacterial artificial chromosomes (BAC) flanking MSANTD3, CTD-3186I20 Cy5 (telomeric) and CTD-2363K7 Cy3 (centromeric) (BACPAC Resources Center, Children’s Hospital Oakland Research Institute). Custom FISH probes for the ZNF217 locus were CTD-2552P20 Cy5 (telomeric) and CTD-2511E9 Cy3 (centromeric). Break-apart FISH was done as previously described [22]. Briefly, TMA sections (6μm) were pretreated with citric acid buffer (pH 6.0). BACs were directly labeled with either Cy5 or Cy3 (GE Healthcare Life Sciences) and then hybridized using Vysis reagents and protocols. Slides were counterstained with 4,6-diamidino 2-phenylindole for microscopy, and images captured using Ariol software (Applied Imaging). For each case, 100 nuclei were evaluated and cases scored positive for rearrangement if ≥30 breaks of the two probes were present. Cases with poor FISH probe hybridization were considered unevaluable, and excluded from subsequent analysis.

Immunohistochemistry

MSANTD3 protein expression was evaluated by immunohistochemistry using an anti-MSANTD3 antibody (LS-C146308, 1:2400 dilution; LifeSpan Biosciences) and peroxidase-based chromogenic staining (EnVision, Dako). All slides were uploaded to the Stanford Tissue Microarray Database [23]. Cores were evaluated for nuclear staining and assigned a score of strong (2), moderate (1), weak (+/-), negative (-), or uninterpretable/missing core (<100 evaluable nuclei). Strong staining was defined as intense staining in >30% or faint staining.
in > 70% of nuclei; moderate staining as intense staining in 5–30% or faint staining in 30–70% of nuclei; weak staining as intense staining in 0–5% or faint staining in 10–30% of nuclei; and negative staining as faint staining in <10% of nuclei. Images were independently evaluated using color segmentation software (GemIdent). Briefly, GemIdent was trained to recognize positive and negative nuclei, and a percentage of positive staining was calculated. Since GemIdent could not readily distinguish intensities, the algorithm of < 9% staining was defined as negative, 9–14% as weak, 14–26% as moderate, and >26% as strong. Discrepancies between the manual and automated scores were further reviewed and a final score assigned by the pathologist.

Phylogenetic studies
Conserved protein domains within MSANTD3 were identified by search of NCBI's conserved domain database [24]. Local protein sequence alignments were performed using the Multiple Alignment Construction and Analysis Workbench (MACAW) [25]. Global protein sequence-alignments were performed using ClustalX [26]. A boot-strapped phylogenetic tree was displayed with TreeView [27].

Cell culture studies
SMG-C6 cells, an SV40-immortalized rat submandibular salivary gland acinar cell line [28] (kind gift of Dr. Margarita M. Vasquez, University of Texas Health Science Center at San Antonio), were grown in DMEM/F12 media supplemented as described [29]. NIH-3T3 mouse embryo fibroblasts were obtained from the ATCC and grown in DMEM media supplemented with 10% bovine calf serum. A human C-terminally Myc-tagged MSANTD3 cDNA ORF clone was obtained from Origene (SKU:RC203850), and then subcloned into pLentiCMV-Puro (Addgene #17452) to create pLentiCMV-MSANTD3. pLentiCMV-MSANTD3 or empty vector control was packaged in 293T cells (ATCC) using ViraPower Lentiviral Packaging Mix (Thermo Fisher Scientific), and then transduced into SMG-C6 cells and selected with 4 μg/ml puromycin. Western blotting was done as previously described [30], using anti-MSANTD3 antibody (LS-C146308, 1:1000 dilution; LifeSpan Biosciences) and anti-Myc antibody (9B11, 1:500 dilution; Cell Signaling). For cell proliferation assays, cells were plated in 6-well plate wells (20,000 cells per well in triplicate) and cell proliferation determined 1, 3 and 5 days later by Wst-1 assay (Roche). For contact-inhibition studies, NIH-3T3 cells were transduced with pLentiCMV-MSANTD3, KRAS(V12) positive-control, or empty vector control as above, and selected in 2 μg/ml puromycin. One million cells were plated per 10 cm dish in triplicate, and 16 days later cells were fixed with methanol, stained with 0.5% crystal violet (in 25% methanol), and then foci ≥ 3 mm counted. For SMG-C6 transcriptome studies, RNA was isolated with RNeasy (Qiagen), and then the TruSeq RNA Sample Preparation Kit v2 (Illumina) used to prepare barcoded-sequence libraries, which were sequenced on an Illumina HiSeq2000 instrument (101bp paired reads) to 36–49 million reads. Reads were aligned to the rat genome using DNAnexus, which also provided reads per kilobase transcript per million mapped reads (RPKM). Non-expressed genes (RPKM < 1) were filtered, and gene RPKM ratios (MSANTD3/empty vector) calculated. Differentially-expressed gene sets were then identified using Gene Set Enrichment Analysis (GSEA) [31], with the ‘pre-ranked’ option and default settings. RNA-seq reads are available at GEO (accession GSE76354).
Results

Transcriptome sequencing identifies novel gene fusions in acinic cell carcinoma

As part of a broader transcriptome survey to discover novel oncogenic gene fusions or mutations in less common cancer diagnoses that are available mainly as archived FFPE tissue blocks [14], here we carried out whole-transcriptome sequencing of three prototypic AcCC cases. Illumina sequencing libraries were constructed from rRNA-depleted total RNA, and Illumina paired-end sequencing (75bp x 2) was done to a depth of 103–110 million reads per case. To discover gene fusions, evidenced by paired sequencing reads mapping to two different genes and/or reads spanning predicted fusion junctions, we used four different software tools: Chimeriscan [15], TopHat-Fusion [16], SnowShoes-FTD [17], and deFuse [18]. All four algorithms identified a total of two fusion genes, both novel, and one in each of two different AcCC cases.

The first novel chimeric transcript resulted from fusion of noncoding exon 1 of Histatin 3 (HTN3; cytoband 4q13.3) to exon 2 (the first coding exon) of Myb/SANT-like DNA-binding domain contain 3 (MSANTD3; cytoband 9q31.1) (Fig 1A). The fusion junction was supported by 51 junction-spanning reads (with 28 unique reads; S1 Fig). Consequent to the rearrangement, the promoter of a highly-expressed salivary gland gene, the microbial peptide precursor HTN3 [32], ostensibly drives overexpression of MSANTD3, an uncharacterized protein harboring a Myb/SANT-like domain characteristic of the MYB oncoprotein and SANT family proteins [33].

The second chimera resulted from fusion of exon 2 of Proline-rich protein BstNI subfamily 3 (PRB3; cytoband 12p13.2) to exon 2 (the first coding exon) of Zinc finger protein 217 (ZNF217; cytoband 20q13.2) (Fig 1B). The fusion junction was supported by 78 junction-spanning reads (with 36 unique reads; S2 Fig). The rearrangement results in the promoter of another highly-expressed salivary gland gene, PRB3 [34], possibly driving overexpression of ZNF217, a reported oncoprotein in several cancer types [35]. However, the start codon (ATG) of ZNF217 is out of frame relative to the normal PRB3 open reading frame (Fig 1B), and therefore generation of ZNF217 protein would necessitate internal initiation of translation.

FISH analysis reveals recurrent MSANTD3 rearrangement in acinic cell carcinoma

To validate MSANTD3 rearrangement in the index case, and to identify possible MSANTD3 rearrangements in additional AcCC cases, we developed a ‘break-apart’ FISH assay. In this assay, differentially fluorescently-labeled FISH probes flanking the MSANTD3 locus would appear co-localized in normal interphase nuclei, but physically-separated in nuclei harboring allelic rearrangement at the locus. We carried out break-apart FISH on a tissue microarray comprising 27 different AcCC cases, including the three cases evaluated by RNA-seq. In all, 3 of the 20 evaluable cases (including the index case) exhibited break-apart rearrangement of MSANTD3 locus (Table 1 and Fig 2A–2C), validating the rearrangement in the index case, and estimating the recurrence rate to be 15%. In all three FISH-positive cases, the rearrangement was heterozygous (i.e. affecting only one MSANTD3 allele), consistent with a dominantly acting oncogene. A fourth AcCC case showed isolated loss of the telomeric FISH probe (downstream of MSANTD3) (Table 1), a finding with uncertain expected impact on MSANTD3 expression.

We developed an analogous ‘break-apart’ FISH assay for the ZNF217 locus. In all, 13 of the 27 cases were evaluable (i.e. sufficient FISH hybridization signal), and only the index case
scored positive for ZNF217 (heterozygous) locus rearrangement (Fig 2D). Thus, while we validated rearrangement in the index case, we did not find evidence for recurrent rearrangement. As such, our subsequent studies focused on the recurrent MSANTD3 rearrangement.

MSANTD3 is highly expressed in a subset of acinic cell carcinomas

In the index case, the HTN3 promoter ostensibly drives the overexpression of a chimeric transcript encoding full-length MSANTD3 protein. To evaluate MSANTD3 protein expression, we carried out immunohistochemistry on the above TMA. Of 27 AcCC cases, 8 (30%) were strongly positive for MSANTD3 diffuse nuclear-staining (the expected cellular compartment for Myb/SANT domain-containing proteins) (Table 1 and Fig 2E–2G). The 8 IHC strongly-positive cases included all 3 cases with MSANTD3 rearrangement, a statistically-meaningful enrichment ($P = 0.02$; two-tailed Fisher’s exact test). Also noteworthy, 7 of the 27 AcCC cases...
demonstrated extensive lymphocytic infiltration (a common finding in AcCC; [36]), and all 7 were among the 18 cases that expressed MSANTD3 to some degree (Table 1) \((P = 0.06, \text{ two-tailed Fisher’s exact test})\); albeit, all 7 cases were FISH-negative for MSANTD3 rearrangement. The meaning of this association is unclear.

**MSANTD3 expression varies across other neoplasias of the salivary gland and diverse tissue types**

Since MSANTD3 was an unstudied protein, we sought to characterize its expression across a wider array of benign and malignant tissues. Towards this goal, we carried out IHC staining of 11 previously described TMAs, altogether comprising 1293 evaluable cases representing normal and neoplastic tissues of the salivary gland, brain, head and neck, gastrointestinal, cardiovascular, respiratory, immunologic, endocrine, integumentary and musculoskeletal systems. Of these, 258 cases were of salivary origin, and the remaining 1035 cases were from other organ systems and included 235 normal tissues, 70 embryonic tissues, 55 benign or pre-malignant tissues, 40 benign neoplasms and 635 malignant neoplasms.

---

Table 1. Acinic cell carcinoma cases.

| Case | MSANTD3 FISH   | MSANTD3 IHC score | ZNF217 FISH | RNA-seq fusion | Lymphocytic infiltrate\(^b\) |
|------|----------------|-------------------|-------------|----------------|-----------------------------|
| 1    | BREAK APART    | Strong            | Normal      | HTN3-MSANTD3    | No                          |
| 2    | BREAK APART    | Strong            | Normal      |                | No                          |
| 3    | BREAK APART    | Strong            | Normal      |                | No                          |
| 4    | Normal         | Strong            | Normal      |                | YES                         |
| 5    | Normal         | Strong            | Normal      |                | YES                         |
| 6    | Normal         | Strong            | Normal      |                | No                          |
| 7    | Normal         | Strong            | Normal      |                | No                          |
| 8    | Not scorable   | Strong            | BREAK APART | PRB3-ZNF217    | No                          |
| 9    | Normal         | Moderate          | Normal      |                | YES                         |
| 10   | Normal         | Moderate          | Normal      |                | YES                         |
| 11   | Normal         | Moderate          | Normal      |                | No                          |
| 12   | Not scorable   | Moderate          | Normal      |                | No                          |
| 13   | Normal         | Weak              | Normal      |                | YES                         |
| 14   | Normal         | Weak              | Normal      |                | YES                         |
| 15   | Normal         | Weak              | Normal      |                | YES                         |
| 16   | Normal         | Weak              | Normal      |                | No                          |
| 17   | Normal         | Weak              | Normal      |                | No                          |
| 18   | Not scorable   | Weak              | Normal      |                | No                          |
| 19   | Loss of red signal | Negative    | Normal      |                | No                          |
| 20   | Normal         | Negative          | Normal      |                | None identified             |
| 21   | Normal         | Negative          | Normal      |                | No                          |
| 22   | Normal         | Negative          | Normal      |                | No                          |
| 23   | Normal         | Negative          | Normal      |                | No                          |
| 24   | Normal         | Negative          | Normal      |                | No                          |
| 25   | Not scorable   | Negative          | Normal      |                | No                          |
| 26   | Negative       | Negative          | Normal      |                | No                          |
| 27   | Negative       | Negative          | Normal      |                | No                          |

\(^a\) Ordered by MSANTD3 IHC score

\(^b\) Defined as lymphocytic infiltrate greater than 30%

doi:10.1371/journal.pone.0171265.t001
With respect to the salivary gland tissues (Table 2 and Fig 3A and 3B), MSANTD3 was expressed in normal salivary gland ductal cells to varying degrees. However, acinar cells were most often entirely negative (24/33 cases), or displayed weak staining (5/33) and at most moderate staining (4/33). While 51% of salivary specimens (benign and malignant) tested were void of any MSANTD3 staining, strong MSANTD3 expression was observed in a substantial subset of mucoepidermoid carcinomas (5/25, 20%) and adenosquamous carcinomas (3/5, 60%). FISH performed on 120 of the salivary gland neoplastic cases (other than AcCC) identified no additional MSANTD3 rearrangements. To exclude the possibility that our MSANTD3 antibody might cross react with MYB (itself rearranged in a subset of salivary gland tumors), IHC-staining for MYB was performed and compared with MSANTD3 staining across 172 cases and no correlation was observed (data not shown).

Beyond the salivary gland (Table 3 and Fig 3C–3P), MSANTD3 was expressed in a small subset of normal cell types and in many neoplasms. In normal tissues, expression was identified in spermatogonia and early spermatocytes, the parietal cells of stomach, tubular and parietal epithelial cells of the kidney, cortical cells of the adrenal gland, uterine endometrium and the glandular epithelium of the prostate.

Expression in carcinoma was more prominent, with strong expression in multiple gonadally-derived carcinomas, adenocarcinomas of the stomach, lung, pancreas, endometrium, and bladder, as well as, papillary thyroid carcinoma, hepatocellular carcinoma, urothelial carcinoma and a subset of invasive breast cancers. In contrast, MSANTD3 expression was rarely observed in normal and neoplastic tissues of the brain, head and neck region, esophagus, integument, musculoskeletal system, lymphovascular system, small bowel and large bowel.

Fig 2. Evaluation of MSANTD3 rearrangement and protein expression in acinic cell carcinoma tissue sections. (A-C) Break-apart FISH assay of MSANTD3 locus rearrangement; green FISH probe is flanking centromeric and red FISH probe is flanking telomeric to MSANTD3. Note positive rearrangement (evidenced by physically-separated green and red signals, arrows) in AcCC case (A). AcCC case (B) is negative for the rearrangement (i.e., signals co-localize), as is observed in normal salivary gland control (C). (D) Break-apart FISH assay of ZNF217 rearrangement, confirming the rearrangement in the index case. (E-G) Corresponding MSANTD3 immunostaining of the above cases. Note the strong nuclear MSANTD3 staining (E) corresponding to the FISH-positive rearranged specimen.

doi:10.1371/journal.pone.0171265.g002
Also, tubularly-derived carcinomas of the kidney did not exhibit staining, an interesting finding considering the prominent expression in normal kidney tubules. Analysis of publicly-available The Cancer Genome Atlas (TCGA) RNA-seq data also showed varied MSANTD3 transcript levels across cancer types, with several exhibiting significantly higher expression in cancer compared to matched normal tissue (S3 Fig).

In addition, because we had stained a large number of breast cancers and had clinical outcome parameters on these specimens, we attempted to identify clinicopathologic correlates. We found no correlation between MSANTD3 expression and ER or HER2 status, nor did we identify a significant correlation with survival \((P = 0.18, \text{log-rank test})\).

**MSANTD3 protein is highly conserved among tetrapods**

Because little was known about MSANTD3, we also examined its evolutionary conservation to infer function and to identify possible relevant model organisms. Human MSANTD3 comprises 275 amino acids, with a predicted molecular weight of 32 kD. A search for conserved protein domains identified only the Myb/SANT domain within the N-terminus (Fig 4A).

Analysis of amino acid conservation across species revealed MSANTD3 to be highly conserved in mammals (human), birds (chicken), reptiles (python), and amphibians (frog), but far less conserved in ray-finned fish (cichlid) (Fig 4B–4D). Even more distantly related MSANTD3-like proteins are present in invertebrates (Ciona, sea urchin, and fruit fly). There appeared to be no MSANTD3-related gene in nematode worms, plants, fungi, or bacteria. The MSANTD3 homolog in cichlids (bony fish) is about as distant from other vertebrates as is the insect gene. Other fish (e.g. fugu and zebrafish) have even more distantly related genes. Interestingly, the

### Table 2. MSANTD3 immunostaining of salivary gland benign and malignant specimens.

| Salivary gland | Immunostaining score (number of cases, %) |
|---------------|------------------------------------------|
|               | Strong | % | Moderate | % | Weak | % | Negative | % | Total |
| Normal        |        |   |          |   |       |   |          |   |       |
| Adult         | 0      | 0%| 4        | 12%| 5    | 15%| 24       | 73%| 33    |
| Embryonic     | 0      | 0%| 0        | 0%| 0    | 0%| 2        | 100%| 2     |
| Benign        |        |   |          |   |       |   |          |   |       |
| Pleomorphic Adenoma | 2 | 4%| 5        | 10%| 11   | 22%| 32       | 64%| 50    |
| Basal Cell Adenoma | 0 | 0%| 0        | 0%| 0    | 0%| 1        | 100%| 1     |
| Monomorphic Adenoma | 0 | 0%| 0        | 0%| 0    | 0%| 1        | 100%| 1     |
| Oncocytoma    | 1      | 9%| 2        | 18%| 4    | 36%| 4        | 36%| 11    |
| Oncocytic Hyperplasia | 2 | 67%| 0       | 0%| 1    | 33%| 0        | 0%| 3     |
| Oncocytic Cystadenoma | 0 | 0%| 0        | 0%| 1    | 100%| 0       | 0%| 1     |
| Myoepithelioma | 0      | 0%| 0        | 0%| 1    | 17%| 5        | 83%| 6     |
| Warthin Tumor | 1      | 100%| 0       | 0%| 0    | 0%| 0        | 0%| 1     |
| Malignant     |        |   |          |   |       |   |          |   |       |
| AcCC: MSANTD3 Rearrangement | 3 | 100%| 0       | 0%| 0    | 0%| 0        | 0%| 3     |
| AcCC: Normal MSANTD3 FISH | 3 | 18%| 3       | 18%| 5    | 29%| 6        | 35%| 17    |
| AcCC: MSANTD3 FISH not evaluable | 2 | 29%| 1       | 14%| 1    | 14%| 3        | 43%| 7     |
| Adenocarcinoma NOS | 1 | 8%| 1       | 8%| 3    | 23%| 8        | 62%| 13    |
| Adenoid Cyst Carcinoma | 3 | 5%| 13      | 22%| 15   | 25%| 28       | 47%| 59    |
| Adenosquamous Carcinoma | 3 | 60%| 0       | 0%| 1    | 20%| 1        | 20%| 5     |
| Basal Cell Adenocarcinoma | 0 | 0%| 0       | 0%| 0    | 0%| 1        | 100%| 1     |
| Mucoepidermoid | 5      | 20%| 8       | 32%| 5    | 20%| 7        | 28%| 25    |
| Myoepithelial | 0      | 0%| 1       | 20%| 1    | 20%| 3        | 60%| 5     |
| Salivary Duct Carcinoma | 1 | 33%| 2       | 67%| 0    | 0%| 0        | 0%| 3     |
| NOS           | 0      | 0%| 1       | 33%| 1    | 33%| 1        | 33%| 3     |
| **Total**     | 27     | 10%| 41      | 16%| 58   | 22%| 132      | 51%| 258   |

doi:10.1371/journal.pone.0171265.t002
coelacanth, a lobe-finned fish that is thought to be related to a common ancestor of all tetrapods [37], has an MSANT3 protein more similar to those of land vertebrates. Furthermore, the vertebrate and coelacanth proteins share homologous regions outside of the N-terminal Myb/SANT domain that are poorly conserved in other species.

**MSANTD3 overexpression upregulates genes functioning in protein synthesis**

Recurrent rearrangement of *MSANTD3* in AcCC, ostensibly driving overexpression of the full-length MSANTD3 protein, combined with observed overexpression by IHC, strongly suggested an oncogenic driver role in AcCC. To preliminarily characterize potential oncogenic functions, we used lentiviral transduction to engineer MSANTD3 overexpression in cultured cells, first using an immortalized rat submandibular salivary gland acinar cell line model [28], SMG-C6. Overexpression of MSANTD3 in SMG-C6 cells, confirmed by western blot (Fig 5A).

**Fig 3. Representative images of MSANTD3 immunostaining in select tissues.** (A) Normal salivary tissue, (B) Mucoepidermoid carcinoma, (C) Normal breast tissue, (D) Invasive breast carcinoma, not otherwise specified, (E) Normal bladder, (F) Urothelial carcinoma, (G) Normal prostate, (H) Normal stomach, (I) Normal kidney, (J) Fetal kidney, (K) Normal liver, (L) Hepatocellular carcinoma, (M) Normal testicle, (N) Seminoma, (O) Testicular atrophy, and (P) Adrenal cortex. Images were acquired at 40x magnification.

doi:10.1371/journal.pone.0171265.g003
Table 3. MSANTD3 immunostaining across diverse benign and neoplastic tissues.

| Tissue            | MSANTD3 strong immunostaining (No. cases) | Total No. cases | % strongly positive |
|-------------------|------------------------------------------|-----------------|---------------------|
| **Testis**        |                                          |                 |                     |
| Normal            | 14                                       | 14              | 100%                |
| Atrophic/Immature | 0                                        | 4               | 0%                  |
| Seminoma          | 19                                       | 22              | 86%                 |
| Teratoma          | 2                                        | 3               | 67%                 |
| Yolk Sac Tumor    | 4                                        | 4               | 100%                |
| Embryonal Carcinoma | 1                                       | 2               | 50%                 |
| Granulosa Cell Tumor | 1                                      | 1               | 100%                |
| Leydig Cell Tumor | 0                                        | 1               | 0%                  |
| **Adrenal**       |                                          |                 |                     |
| Normal Cortex     | 14                                       | 22              | 64%                 |
| Adenoma           | 1                                        | 3               | 33%                 |
| Adrenocortical Carcinoma | 1                              | 2               | 50%                 |
| Pheochromocytoma  | 0                                        | 2               | 0%                  |
| **Bladder**       |                                          |                 |                     |
| Normal            | 0                                        | 7               | 0%                  |
| Embryonic         | 0                                        | 2               | 0%                  |
| Adenocarcinoma    | 2                                        | 3               | 67%                 |
| Urothelial Carcinoma | 3                                       | 14              | 21%                 |
| **Breast**        |                                          |                 |                     |
| Normal            | 0                                        | 7               | 0%                  |
| Invasive Ductal   | 4                                        | 11              | 36%                 |
| Invasive Lobular  | 2                                        | 3               | 67%                 |
| Invasive NOS      | 75                                       | 248             | 30%                 |
| **Kidney**        |                                          |                 |                     |
| Normal            | 11                                       | 13              | 85%                 |
| Embryonic         | 0                                        | 5               | 0%                  |
| Oncocytoma        | 0                                        | 2               | 0%                  |
| Clear Cell Carcinoma | 0                                        | 1               | 0%                  |
| Conventional Carcinoma | 0                                    | 4               | 0%                  |
| Papillary Carcinoma | 0                                       | 4               | 0%                  |
| **Liver**         |                                          |                 |                     |
| Normal            | 0                                        | 11              | 0%                  |
| Hepatocellular    | 4                                        | 10              | 40%                 |
| **Lung**          |                                          |                 |                     |
| Normal            | 0                                        | 7               | 0%                  |
| Andenocarcinoma   | 8                                        | 14              | 57%                 |
| **Ovary**         |                                          |                 |                     |
| Normal            | 0                                        | 7               | 0%                  |
| Mucinous Carcinoma | 2                                        | 3               | 67%                 |
| Clear Cell Carcinoma | 3                                       | 4               | 75%                 |
| Serous Carcinoma  | 3                                        | 5               | 60%                 |
| **Prostate**      |                                          |                 |                     |
| Normal            | 3                                        | 6               | 50%                 |
| Adenocarcinoma    | 7                                        | 12              | 58%                 |
| **Stomach**       |                                          |                 |                     |
| Normal            | 3                                        | 10              | 30%                 |
| Adenocarcinoma    | 5                                        | 7               | 71%                 |
| **Thyroid**       |                                          |                 |                     |
| Normal            | 0                                        | 12              | 0%                  |
| Papillary Carcinoma | 2                                       | 5               | 40%                 |
| Follicular Carcinoma | 1                                       | 2               | 50%                 |
| **Pancreas**      |                                          |                 |                     |
| Normal            | 0                                        | 3               | 0%                  |
| Adenocarcinoma    | 1                                        | 2               | 50%                 |
| Ductal            | 2                                        | 3               | 67%                 |
| **Uterus**        |                                          |                 |                     |
| Endometrium       | 2                                        | 3               | 67%                 |
| Endometrial Carcinoma | 7                                       | 11              | 64%                 |
| Leiomyosarcoma    | 0                                        | 5               | 0%                  |

doi:10.1371/journal.pone.0171265.t003
did not enhance cell proliferation (Fig 5B). Nor did overexpression of MSANTD3 in NIH-3T3 mouse embryo fibroblast cells result in lost contact-inhibition (assayed by focus formation; S4 Fig). To explore potential oncogenic phenotypes more broadly, we profiled transcriptomic changes by RNA-seq in SMG-C6 cells overexpressing MSANTD3, compared to empty vector control. By Gene Set Enrichment Analysis, MSANTD3 overexpression led to marked upregulation of multiple gene sets associated with protein synthesis, including ‘ribosome’, ‘peptide chain elongation’, and ‘translation’ (Fig 5C and S1 Table).
Recurrent chromosomal rearrangements (and the resultant gene fusions) are known to characterize other salivary gland tumors, but have not previously been reported in AcCC. Here, by whole-transcriptome profiling of three AcCC cases, we discovered two novel fusion genes, HTN-MSANTD3 and PRB3-ZNF217, and found that MSANTD3 locus rearrangements are recurrent events observed in approximately 15% of AcCC cases. Furthermore, in a cell line model, MSANTD3 overexpression led to the upregulation of genes involved in protein synthesis, a cellular process often upregulated in cancer [38].

Notably, both novel fusion genes juxtapose a highly-expressed salivary gland gene (HTN3 or PRB3) to the full-length 3' partner (MSANTD3 and ZNF217, respectively), ostensibly driving the overexpression of a chimeric transcript encoding the full-length 3' fusion partner. For the MSANTD3 rearrangement, we showed by immunostaining that MSANTD3 protein was in fact highly expressed in all three cases with DNA rearrangement. Though we note that for the other two cases with MSANTD3 rearrangement, the FFPE tissue blocks were exhausted and so we did not have the opportunity to identify a putative 5' fusion partner, which may or may not

![Figure 5](https://example.com/msantd3.png)

**Fig 5.** MSANTD3 overexpression leads to the upregulation of genes involved in protein synthesis. (A) Overexpression of C-terminally Myc-tagged MSANTD3 in SMG-C6 immortalized rat salivary gland epithelial cells, demonstrated by western blot using anti-MSANTD3 antibody (left) and anti-Myc tag antibody (right). Note, the observed band runs close to the calculated MW of the tagged protein (36 kD). (B) MSANTD3 overexpression does not enhance cell proliferation, compared to empty vector control, quantified by Wst-1 assay. (C) Transcriptome (RNA-seq) analysis of MSANTD3 overexpression identifies significant upregulation of gene sets associated with protein synthesis. Gene Set Enrichment Analysis (GSEA) of the top gene set ('KEGG Ribosome') is shown; other significant gene sets are listed in S1 Table. Note, the early and positive upswing of the Enrichment profile reflects the early concentration of ribosome genes within the ranked list of genes upregulated by MSANTD3 overexpression (compared to empty vector control).

doi:10.1371/journal.pone.0171265.g005

**Discussion**

Recurrent chromosomal rearrangements (and the resultant gene fusions) are known to characterize other salivary gland tumors, but have not previously been reported in AcCC. Here, by whole-transcriptome profiling of three AcCC cases, we discovered two novel fusion genes, HTN-MSANTD3 and PRB3-ZNF217, and found that MSANTD3 locus rearrangements are recurrent events observed in approximately 15% of AcCC cases. Furthermore, in a cell line model, MSANTD3 overexpression led to the upregulation of genes involved in protein synthesis, a cellular process often upregulated in cancer [38]. Notably, both novel fusion genes juxtapose a highly-expressed salivary gland gene (HTN3 or PRB3) to the full-length 3' partner (MSANTD3 and ZNF217, respectively), ostensibly driving the overexpression of a chimeric transcript encoding the full-length 3' fusion partner. For the MSANTD3 rearrangement, we showed by immunostaining that MSANTD3 protein was in fact highly expressed in all three cases with DNA rearrangement. Though we note that for the other two cases with MSANTD3 rearrangement, the FFPE tissue blocks were exhausted and so we did not have the opportunity to identify a putative 5' fusion partner, which may or may not
also be HTN3. Notably, MSANTD3 protein was highly expressed in an additional 5 cases (for 30% of all cases), presumably upregulated by some mechanism other than genomic DNA rearrangement.

With respect to the PRB3-ZNF217 fusion, ZNF217 is a zinc finger protein, a protein family often functioning in transcriptional regulation through sequence-specific DNA binding [39]. ZNF217 was first characterized as the ‘driver’ oncogene amplified at 20q13.2 in breast cancer [40], where it was found to promote cellular immortalization [40]. Since then, ZNF217 has been implicated in ovarian and other cancer types, where it has been linked to diverse oncogenic phenotypes including cell proliferation, survival, and invasion [35]. Although we have not found ZNF217 rearrangements in other AcCC cases, and we have not demonstrated ZNF217 protein expression, given its known oncogenic functions in other cancers it is intriguing to speculate a possible pathogenic role in a subset of AcCC cases.

In contrast, the recurrent nature of MSANTD3 gene rearrangements provides strong genetic support for its pathogenic role. MSANTD3 is a previously unstudied gene, named for harboring a protein domain with shared homology to the DNA-binding domains of MYB and SANT-family proteins. MYB, the homolog of the avian myeloblastosis viral oncogene, functions in normal hematopoiesis, and deregulated MYB expression has been linked with human leukemia [41]. SANT is an acronym for switching-defective protein 3 (Swi3), adaptor 2 (Ada2), nuclear receptor co-repressor (N-CoR), transcription factor (TF)IIIB, with the four proteins (and others since) found to share a conserved 50 amino-acid motif with the MYB DNA-binding domain [33]. SANT domains are often present within subunits of chromatin-remodeling and histone-modifying complexes [42]. It was initially hypothesized that all SANT domains bind directly to DNA to enable their regulatory function. Structural and biochemical evidence for this model has been provided in at least some cases [43–45]. However, it has also been hypothesized that some SANT domains may bind directly to histones rather than to DNA in order to regulate chromatin structure and function [42].

Interestingly, in a recent yeast two-hybrid screen to identify binding partners of methyltransferase enzymes [46], MSANTD3 (formerly known as C9orf30) was identified as one of many putative binding partners of SUV39H1, itself a histone methyltransferase functioning in establishing heterochromatin [47]. This finding implicates a possible role of MSANTD3 in chromatin regulation, a function consistent with its having a Myb/SANT-like domain. We also note that the observed immunostaining was predominantly nuclear, also consistent with a role in chromatin dynamics. Nonetheless, detailed mechanistic studies will be necessary to elucidate the protein’s normal function.

To further explore MSANTD3 biology, we carried out a broad immunostaining survey of diverse normal and neoplastic tissues. Within the normal salivary gland, MSANTD3 generally showed higher expression in ductal compared to acinar cells. MSANTD3 was also expressed in a subset of other salivary gland neoplasias, though without evidence of locus rearrangement. Other tissues that stained strongly included normal testis and kidney, and glandular tissues including prostate and endometrium. Adenocarcinomas of diverse organ sites showed varied staining, while squamous cell carcinomas, sarcomas, and lymphoid-derived neoplasias were generally void of staining. The expression of MSANTD3 across diverse tissue types, as well as its protein conservation down to amphibians, suggests an important cellular function(s). Those functions, as well as possible roles in diseases beyond AcCC, remain to be explored.

To further characterize its pathogenic role in AcCC, we overexpressed MSANTD3 in SMG-C6 immortalized rat salivary gland epithelial cells, a reasonable approximation of a normal cell type equivalent. MSANTD3 overexpression did not enhance cell proliferation. However, by expression profiling we found that its overexpression led, either directly or indirectly, to marked upregulation of genes involved in translation of mRNA into proteins by ribosomes.
This finding is intriguing because increased protein synthesis is a common feature of cancers [38]. Oncoproteins including PI3-kinases, AKT kinase, ribosomal S6 kinase, and MYC are all thought to act in large part by enhancing ribosome biogenesis and translation, to provide needed new proteins for cell growth and proliferation [48, 49].

Of note, in a recent RNA-seq survey of cancer cell lines, a XRCC4-MSANTD3 in-frame fusion was reported in SW780 bladder transitional cell carcinoma cells [50] (their Supplementary Table 8). However, that fusion was supported by only two sequencing reads, and the predicted fusion incorporates only the terminal exon of MSANTD3 and so would be missing the highly-conserved Myb/SANT-like domain), and thus is unlikely to be functional.

Although the exact role(s) of MSANTD3 in AcCC oncogenesis remain to be determined, it is also intriguing that MYB itself, which of course also harbors a Myb/SANT-like domain, is part of a gene fusion that characterizes a different salivary gland tumor: MYB-NFIB in adenoid cystic carcinoma. Perhaps this finding suggests a more general role of Myb/SANT-like DNA-binding domain containing proteins in the normal biology and neoplastic conversion of salivary epithelium.

From a diagnostic standpoint, several salivary gland neoplasias have been found to harbor specific gene fusions that have proven to be useful biomarkers for differential diagnosis [6]. In our study, we have identified MSANTD3 rearrangements in 15% of AcCC specimens, and in no other salivary gland neoplasias. While its modest frequency in AcCC would limit its overall diagnostic utility, finding MSANTD3 rearrangement (e.g. by FISH) in a diagnostically challenging case could nonetheless provide support for a diagnosis of AcCC. Whether MSANTD3 rearrangement and/or overexpression confer a distinct prognosis remains unanswered, and need await studies on larger cohorts with clinical follow up.

In summary, by whole-transcriptome sequencing of archival AcCC cases and validation by FISH, we have discovered novel gene fusions including a recurrent rearrangement of the previously uncharacterized gene MSANTD3. Functional studies implicate a role of MSANTD3 in upregulating translation; however, the normal and tumorigenic mechanisms of this novel putative oncogene await future investigation. Based on our studies, AcCC now joins other salivary gland neoplasias in harboring specific chromosome rearrangements, and may ultimately aid in the diagnosis and understanding of disease pathogenesis.

Supporting information

S1 Fig. HTN3-MSANTD3 junction-spanning reads. Shown are the 51 sequencing reads spanning the predicted HTN3-MSANTD3 junction, identified from the Chimeriscan analysis. (PDF)

S2 Fig. PRB3-ZNF217 junction-spanning reads. Shown are the 78 sequencing reads spanning the predicted PRB3-ZNF217 junction, identified from the Chimeriscan analysis. (PDF)

S3 Fig. MSANTD3 transcript levels vary across cancer types. Plots display normalized transcript levels for cancer vs. normal samples, shown for those TCGA cancer types where there are sufficient sample numbers to perform a statistical analysis (tumor vs. normal; Wilcoxon P-value indicated). Plots assembled using Wanderer (see Methods). (PDF)

S4 Fig. MSANTD3 overexpression does not lead to loss of contact-inhibition (focus formation). (A) Focus formation assay in NIH-3T3 cells transduced with pLenti-CMV-MSANTD3 (vs. pLenti-CMV empty vector control), or positive control pBABE-KRAS(V12) (vs. pBABE empty vector control). Crystal violet stained foci were manually counted in triplicate 10cm
plates; representative plates shown. (B) Graphical display of counted foci. Note, no foci (>3mm) were observed following MSANTD3 overexpression.

S1 Table. Canonical pathway gene sets found enriched by GSEA analysis.

Acknowledgments

We wish to thank members of the Pollack and West labs for helpful discussions, and Dr. Adam Kapelner for his assistance with the creation and use of GemIdent.

Author Contributions

Conceptualization: NB KAK RJP RBW JRP.
Formal analysis: NB XG KQ JSL.
Investigation: NB KAK SV JB.
Resources: NX.
Writing – original draft: NB RBW JRP.

References

1. Mittelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007; 7(4):233–45. doi: 10.1038/nrc2091 PMID: 17361217
2. Brenner JC, Chinnaiyan AM. Translocations in epithelial cancers. Biochim Biophys Acta. 2009; 1796(2):201–15. Epub 2009/05/02. doi: 10.1016/j.bbacli.2009.04.005 PMID: 19406209
3. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003; 138(10):819–30. Epub 2003/05/21. PMID: 12755554
4. Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013; 13(10):685–700. Epub 2013/09/26. doi: 10.1038/nrc3580 PMID: 24060861
5. Stenman G. Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol. 2013; 7 Suppl 1:S12–9. Epub 2013/07/04.
6. Stenman G. Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol. 2013; 7 Suppl 1:S12–9. Epub 2013/07/04.
7. Bell D, Hanna EY. Salivary gland cancers: biology and molecular targets for therapy. Curr Oncol Rep. 2012; 14(2):166–74. Epub 2012/01/17. doi: 10.1007/s11912-012-0220-5 PMID: 22246609
8. Weinreb I. Translocation-associated salivary gland tumors: a review and update. Adv Anat Pathol. 2013; 20(6):367–77. Epub 2013/10/12. doi: 10.1097/PAP.0b013e3182a82cc3 PMID: 24113307
9. Mitani Y, Liu B, Rao P, Borra V, Zafereo M, Weber RS, et al. Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clin Cancer Res. 2015. Epub 2015/12/04.
10. Brayer KJ, Frerich CA, Kang H, Ness SA. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. Cancer Discov. 2015. Epub 2015/12/04.
11. Godwin JT, Foote FW Jr., Frazell EL. Acinic cell adenocarcinoma of the parotid gland: report of twenty-seven cases. Am J Pathol. 1954; 30(3):465–77. Epub 1954/05/01. PMID: 13158522
12. Hoffman HT, Karmell LH, Robinson RA, Pinkston JA, Menck HR. National Cancer Data Base report on cancer of the head and neck: acinic cell carcinoma. Head Neck. 1999; 21(4):297–309. Epub 1999/06/22. PMID: 10376748
13. Hall DA, Pu RT. Acinic cell carcinoma of the salivary gland: a continuing medical education case. Diagn Cytopathol. 2008; 36(6):379–85; quiz 86–7. Epub 2008/05/15. doi: 10.1002/dc.20852 PMID: 18478605
14. Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahringer L, Kwei KA, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014; 46(7):722–5. Epub 2014/05/27. doi: 10.1038/ng.2986 PMID: 24859340

15. Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics. 2011; 27(20):2903–4. doi: 10.1093/bioinformatics/btr467 PMID: 21840877

16. Kim D, Salzberg SL. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol. 2011; 12(8):R72. Epub 2011/08/13. doi: 10.1186/gb-2011-12-8-r72 PMID: 21835007

17. Asmann YW, Hossain A, Necela BM, Middha S, Kalari KR, Sun Z, et al. A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. Nucleic Acids Res. 2011; 39(15):e100. Epub 2011/05/31. doi: 10.1093/nar/gkr362 PMID: 21622959

18. McPherson A, Hormozdari F, Zayed A, Giuliany R, Ha G, Sun MG, et al. defuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol. 2011; 7(5):e1001138. Epub 2011/06/01. doi: 10.1371/journal.pcbi.1001138 PMID: 21625565

19. Diez-Villanueva A, Mallona I, Peinado MA. Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenetics Chromatin. 2015; 8:22. Epub 2015/06/27. doi: 10.1186/s13072-015-0014-8 PMID: 26113876

20. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844–7. PMID: 9662379

21. Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkunam Y. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol. 2005; 29(5):617–24. Epub 2005/04/16. PMID: 15832085

22. West RB, Kong C, Clarke N, Gilks T, Lipsick JS, Cao H, et al. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol. 2011; 35(1):92–9. Epub 2010/12/18. doi: 10.1097/PAS.0b013e3182002777 PMID: 21164292

23. Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chenna R, McGettigan PA, McWilliam H, et al. The Stanford Tissue Microarray Database. Nucleic Acids Res. 2008; 36(Database issue):D871–7. doi: 10.1093/nar/gkm861 PMID: 17989087

24. Schuler GD, Altschul SF, Lipman DJ. A workbench for multiple alignment construction and analysis. Proteins. 1991; 9(3):180–90. Epub 1991/01/01. doi: 10.1002/prot.340090304 PMID: 2006136

25. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007; 23(21):2947–8. Epub 2007/09/12. doi: 10.1093/bioinformatics/btm404 PMID: 17846036

26. Page RD. TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci. 1996; 12(4):357–8. Epub 1996/08/01. PMID: 8902363

27. Quissell DO, Barzen KA, Gruenert DC, Redman RS, Camden JM, Turner JT. Development and characterization of SV40 immortalized rat submandibular acinar cell lines. J Virol. 1993; 61(10):4434–9. Epub 1993/10/01. PMID: 8406834
35. Cohen PA, Donini CF, Nguyen NT, Lincet H, Vendrell JA. The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value. Oncotarget. 2015. Epub 2015/10/03.

36. Ellis GL, Auclair PL. Tumors of the salivary glands. American Registry of Pathology; Armed Forces Institute of Pathology (US). 2008:Washington, DC: American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology.

37. Amemiya CT, Alfoldi J, Lee AP, Fan S, Philippe H, Macallum I, et al. The African coelacanth genome provides insights into tetrapod evolution. Nature. 2013; 496(7445):311–6. Epub 2013/04/20. doi: 10.1038/nature12027 PMID: 23598338

38. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer. 2003; 3(3):179–92. Epub 2003/03/04. doi: 10.1038/nrc1015 PMID: 12612653

39. Razin SV, Borunova VV, Maksimenko OG, Kandidze OL. Cys2His2 zinc finger protein family: classification, functions, and major members. Biochemistry (Mosc). 2012; 77(3):217–26. Epub 2012/07/19.

40. Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang SI, et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A. 1998; 95(15):8703–8. PMID: 9671742

41. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer. 2008; 8(7):523–34. Epub 2008/06/25. doi: 10.1038/nrc2439 PMID: 18574464

42. Boyer LA, Latek RR, Peterson CL. The SANT domain: a unique histone-tail-binding module? Nat Rev Mol Cell Biol. 2004; 5(2):158–63. Epub 2004/03/26. doi: 10.1038/nrm1314 PMID: 15040448

43. Grune T, Brzeski J, Eberhardt A, Clapier CR, Corona DF, Becker PB, et al. Crystal structure and functional analysis of a nucleosome recognition module of the remodeling factor ISWI. Mol Cell. 2003; 12(2):449–60. Epub 2003/10/11. PMID: 14536084

44. Sharma A, Jenkins KR, Heroux A, Bowman GD. Crystal structure of the chromdomain helicase DNA-binding protein 1 (Chd1) DNA-binding domain in complex with DNA. J Biol Chem. 2011; 286(49):42099–104. Epub 2011/10/29. doi: 10.1074/jbc.C111.294462 PMID: 22033927

45. Yamada K, Frouws TD, Angst B, Fitzgerald DJ, DeLuca C, Schimmele K, et al. Structure and mechanism of the chromatin remodeling factor ISW1a. Nature. 2011; 472(7344):448–53. Epub 2011/04/29. doi: 10.1038/nature09947 PMID: 21525927

46. Weimann M, Grossmann A, Woodsmith J, Ozkan Z, Birth P, Meierhofer D, et al. A Y2H-seq approach defines the human protein methyltransferase interactome. Nat Methods. 2013; 10(4):339–42. Epub 2013/03/05. doi: 10.1038/nmeth.2397 PMID: 23455924

47. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 2000; 406(6869):593–9. Epub 2000/08/19. doi: 10.1038/35020506 PMID: 10949293

48. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005; 5(12):921–8. Epub 2005/12/13. doi: 10.1038/nrc1753 PMID: 16341083

49. van Riggelen J, Yeti A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010; 10(4):301–9. Epub 2010/03/25. doi: 10.1038/nrc2819 PMID: 20332779

50. Kljun C, Durinck S, Stawiaski EW, Haverty PM, Jiang Z, Liu H, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol. 2015; 33(3):306–12. Epub 2014/12/09. doi: 10.1038/nbt.3080 PMID: 25485619